secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001628280-23-010410
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Neoleukin appoints interim CEO and CFO after Drachman resignation; CMO Patel departs
--------------------------------------------------------------------------------

- Donna Cochener appointed Interim CEO; Sean Smith appointed Interim CFO, effective March 31, 2023.
- Dr. Jonathan Drachman resigned as President, CEO and director, effective March 31, 2023 (previously announced March 6).
- Cochener receives base salary $450,000; Smith $410,000; annual bonuses and retention bonuses up to $219,375 and $159,167 respectively.
- CMO Dr. Priti Patel separated; receives 9 months salary continuation, healthcare, and accelerated vesting of 100,000 options.
- Interim officers' severance: 9 months salary plus COBRA; enhanced 15 months lump sum on change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000162828023010410/0001628280-23-010410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000162828023010410/nltx-20230403.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-010410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer